114798-27-5 Usage
Description
[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]is a complex organic compound characterized by its unique molecular structure, which features a biphenyl carboxylic acid core connected to a butyl-4-chloro-5-(hydroxymethyl)-imidazolylmethyl group. This structure endows the compound with a range of potential properties, such as the ability to interact with metal ions and exhibit pharmacological and biological activities. Its specific functions and applications may vary widely, making it a compound of interest for research and industrial uses.
Uses
Used in Pharmaceutical Industry:
[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]is used as a potential pharmaceutical agent for its possible pharmacological and biological activities. [1,1'-Biphenyl]-2-carboxylicacid, 4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-'s unique structure may allow it to interact with specific biological targets, potentially leading to the development of new therapeutics.
Used in Chemical Research:
In the field of chemical research, [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]can be used as a starting material or a building block for the synthesis of more complex molecules. Its ability to act as a ligand for metal ions may also make it a valuable tool in the study of coordination chemistry and catalysis.
Used in Material Science:
[1,1'-Biphenyl]-2-carboxylicacid, 4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-'s structural features may also find applications in material science, where it could be used to develop new materials with specific properties. For example, its potential to interact with metal ions could be exploited in the design of materials with tailored electronic, magnetic, or optical characteristics.
Used in Environmental Applications:
Given its complex structure, [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]may also have potential uses in environmental applications, such as in the development of new methods for the detection, removal, or treatment of pollutants.
Check Digit Verification of cas no
The CAS Registry Mumber 114798-27-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,4,7,9 and 8 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 114798-27:
(8*1)+(7*1)+(6*4)+(5*7)+(4*9)+(3*8)+(2*2)+(1*7)=145
145 % 10 = 5
So 114798-27-5 is a valid CAS Registry Number.
114798-27-5Relevant articles and documents
Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
-
, (2008/06/13)
The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotension II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-[(2′-tetrazol-5-yl)biphenyl-4-il]methyl]-5-(hydroxymethyl)imidazole potassium salt.
Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
-
, (2008/06/13)
A method of treatment for atherosclerosis and/or reducing cholesterol using an angiotensin II antagonist. This method of treatment can be used in conjunction with the treatment of hypertension. Substituted imidazoles such as STR1 are useful as angiotensin II receptor antagonists for this method of treatment. A method of treatment for atherosclerosis and/or reducing cholesterol using an angiotensin II receptor antagonist in combination with an HMG-Co A reductase inhibitor. A method of treatment for atherosclerosis and/or reducing cholesterol using an angiotensin II receptor antagonist in combination with an HMG-Co A reductase inhibitor and an angiotensin converting enzyme inhibitor. Also within the scope of this invention are pharmaceutical compositions for this method of use.
Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl)imidazoles as Potent, Orally Active Antihypertensives
Carini, David J.,Duncia, John V.,Aldrich, Paul E.,Chiu, Andrew T.,Johnson, Alexander L.,et al.
, p. 2525 - 2547 (2007/10/02)
A new series of nonpeptide angiotensin II (AII) receptor antagonists has been prepared.These N-(biphenylylmethyl)imidazoles, e.g. 2-butyl-1--4-chloro-5-(hydroxymethyl)imidazole, differ from the previously reported N-(benzamidobenzyl)imidazoles and related compounds in that they produce a potent antihypertensive effect upon oral administration; the earlier series generally were active only when administered intravenously.It has been found that the acidic group at the 2'-position of the biphenyl is essential.Only ortho-substituted acids possess both high affinity for the AII receptor and good oral antihypertensive potency.The carboxylic acid group has been replaced with a variety of acidic isosteres, and the tetrazole ring has been found to be the most effective.The tetrazole derivative, DuP 753, is currently in development for the treatment of hypertension.
